Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics save search
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.5 3.31% 3.2% 7.4K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Published: 2024-04-17 (Crawled : 20:00) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: -0.51%
H: 0.18%
C: -2.21%
first report for therapeutics financial results
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: 0.0%
H: 2.46%
C: 0.49%
day pipeline therapeutics therapy
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Biopharma Layoff Tracker 2024: Fujifilm, Genentech, Sanofi and More Cut Staff
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
RLYB | News | $1.59 -8.62% -9.43% 280K
|
|
| O: -4.44%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
VXRT | News | $0.7051 -5.41% -5.72% 1.5M
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -2.25%
TXMD | News | $1.88 -0.27% 15K
|
Health Technology
|
| O: 2.63%
H: 3.59%
C: -3.08%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
PTCT | News S | $25.19 -0.87% -0.87% 560K
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -1.33%
NKTR | News | $1.39 -2.11% -2.16% 960K
|
Health Technology
|
| O: -0.67%
H: 1.35%
C: -8.78%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 0.17%
H: 0.39%
C: 0.33%
GLPG | News | $28.78 -2.28% -2.33% 140K
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.78%
AMRN | News | $0.8844 0.13% 0.12% 660K
|
Health Technology
|
| O: 3.69%
H: 0.0%
C: 0.0%
GOOGL | News 4 | $159.18 0.58% 0.58% 22M
|
Technology Services
|
| O: 1.03%
H: 0.94%
C: -0.1%
GOOG | News 4 | $161.05 0.71% 0.7% 19M
|
Technology Services
|
| O: 0.97%
H: 0.95%
C: -0.2%
OCX | News | $2.3 -6.31% -6.74% 41K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: -5.47%
biopharma sanofi
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
GTHX | $3.98 -5.01% -5.28% 340K
|
Health Technology
|
| O: 1.72%
H: 4.82%
C: 3.13%
first therapeutics financial results
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ALLR | $1.37 -3.52% -3.65% 260K
|
n/a
|
| O: -9.52%
H: 0.0%
C: 0.0%
nasdaq extension therapeutics
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
STOK | $11.64 3.47% 3.35% 1.5M
|
Health Technology
|
| O: 0.48%
H: 3.68%
C: -6.31%
commercial therapeutics
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
WINT | $5.085 -10.53% -11.77% 51K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
business key therapeutics financial results
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.14%
H: 0.0%
C: 0.0%
million offering therapeutics
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.33 9.39% 8.58% 170K
|
Health Technology
|
| O: 0.0%
H: 7.32%
C: -1.95%
disease neurology system meeting parkinson’s therapeutics
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Published: 2024-04-17 (Crawled : 00:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K
|
|
| O: 3.32%
H: 8.82%
C: 7.26%
acr-368 acr-2316 pipeline ongoing preclinical for therapeutics oncosignature
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2024-04-16 (Crawled : 22:00) - globenewswire.com
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
|
| O: 3.07%
H: 0.79%
C: -6.75%
offering therapeutics
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.14%
H: 0.0%
C: 0.0%
million offering therapeutics
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
TCRX | News 3 d | $7.39 1.79% 1.76% 91K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
update pipeline therapeutics
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: -1.47%
H: 2.05%
C: -0.59%
nulibry authorization treatment for therapeutics
Pelthos Therapeutics Establishes Board of Directors
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: 0.0%
SVRA | $4.245 -9.49% -10.48% 1M
|
Health Technology
|
| O: -0.79%
H: 6.0%
C: 3.2%
INSM | $25.78 2.02% 1.98% 2.5M
|
Health Technology
|
| O: 0.19%
H: 0.41%
C: -2.68%
therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.